Keyphrases
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
51%
Breast Cancer
39%
Early Breast Cancer
27%
Chemotherapy
26%
Overall Survival
26%
Confidence Interval
20%
Graft-versus-host Disease (GvHD)
18%
Hazard Ratio
17%
Non-relapse Mortality
16%
BRCA1, BRCA2
15%
Acute Myeloid Leukemia
15%
Breast Cancer Patients
14%
Fludarabine
14%
Human Epidermal Growth Factor Receptor 2 (HER2)
14%
Phase II Trial
13%
Trastuzumab
12%
Advanced Breast Cancer
11%
Reduced-intensity Conditioning
11%
Disease-free Survival
11%
Oncotype DX
11%
Progression-free Survival
11%
High Risk
10%
Stem Cell Transplantation
10%
Recurrence Score
10%
BRCA mutation Carriers
10%
Relapsed or Refractory
10%
Triple-negative Breast Cancer
10%
BRCA mutation
9%
Unrelated Donor
9%
Estrogen Receptor-positive
9%
Chimeric Antigen Receptor T-cell Therapy
9%
Tumor
9%
BRCA Carriers
9%
Chimeric Antigen Receptor T Cells (CAR-T)
9%
Metastatic Breast Cancer
9%
Meta-analysis
8%
Non-Hodgkin Lymphoma
8%
Hormone Receptor-positive
8%
Transplantation
8%
Breast Cancer Subtypes
8%
Granulocyte Colony-stimulating Factor (G-CSF)
8%
Anti-CD19 chimeric Antigen Receptor T Cells
8%
Multivariate Analysis
8%
Breast
8%
Patients with Breast Cancer
8%
Glucose-regulated Protein 78 (GRP78)
8%
Treosulfan
7%
Human Epidermal Growth Factor Receptor 2-negative
7%
Ovarian Cancer
7%
Odds Ratio
7%
Medicine and Dentistry
Breast Cancer
100%
Diseases
34%
Overall Survival
27%
Neoplasm
22%
Allogeneic Stem Cell Transplantation
20%
Allogeneic Hematopoietic Stem Cell Transplantation
18%
BRCA1
17%
Acute Myeloid Leukemia
17%
Gamma Urogastrone
16%
Epidermal Growth Factor Receptor 2
15%
Hazard Ratio
14%
Fludarabine
12%
Recurrent Disease
12%
Estrogen Receptor
12%
Stem Cell Therapy
11%
Reduced Intensity Conditioning
11%
Chimeric Antigen Receptor T-Cell
11%
Progression Free Survival
10%
Graft Versus Host Reaction
10%
Non-Hodgkin Lymphoma
10%
Disease Free Survival
9%
Cancer
9%
Germ Cell
9%
Hormone Receptor
9%
Chimeric Antigen Receptor T-Cell Immunotherapy
9%
Non-Relapse Mortality
8%
BRCA Mutation
8%
Trastuzumab
8%
Triple Negative Breast Cancer
8%
Large-Cell Lymphoma
8%
Metastatic Breast Cancer
7%
Myelodysplastic Syndrome
7%
Cohort Analysis
7%
Multivariate Analysis
7%
Cumulative Incidence
7%
Malignant Neoplasm
7%
Ovarian Cancer
7%
Meta-Analysis
7%
Talazoparib
7%
Salvage Therapy
7%
Odds Ratio
6%
Conditioning
6%
Adverse Event
6%
Clinical Trial
6%
Acute Myelogenous Leukemia
6%
Recurrence Risk
6%
Acute Graft Versus Host Disease
6%
Cell Transplantation
6%
Hematopoietic Cell
6%
Prognostic Factor
6%
Pharmacology, Toxicology and Pharmaceutical Science
Breast Cancer
72%
Chemotherapy
39%
Overall Survival
22%
Diseases
18%
Neoplasm
15%
Gamma Urogastrone
12%
Trastuzumab
12%
Metastatic Breast Cancer
12%
Epidermal Growth Factor Receptor 2
11%
Estrogen Receptor
11%
Progression Free Survival
10%
Acute Myeloid Leukemia
9%
Recurrent Disease
8%
Fludarabine
8%
Disease Free Survival
8%
Triple Negative Breast Cancer
7%
Myelodysplastic Syndrome
7%
Granulocyte Colony Stimulating Factor
7%
Remission
7%
Chimeric Antigen Receptor
7%
Cohort Study
6%
Capecitabine
6%
Adverse Event
6%
Cisplatin
6%
Treosulfan
5%
Graft Versus Host Reaction
5%
Nonhodgkin Lymphoma
5%
Phase III Trials
5%
Ovary Cancer
5%
Trastuzumab Deruxtecan
5%
Talazoparib
5%